New concepts of the pathogenesis of alcoholic liver disease lead to novel treatments

被引:101
作者
Lieber C.S. [1 ]
机构
[1] Section of Liver Disease/Nutrition, Bronx VA Medical Center, Mt. Sinai School of Medicine, Bronx, NY 10468
关键词
Stellate Cell; Hepatic Stellate Cell; Alcoholic Liver Disease; Silymarin; Alcoholic Hepatitis;
D O I
10.1007/s11894-004-0027-0
中图分类号
学科分类号
摘要
Activation of methionine to S-adenosylmethionine is depressed in alcoholics. Its repletion opposes alcoholic liver cirrhosis in baboons, decreases mortality in cirrhotic patients, and opposes oxidative stress resulting from cytochrome P4502EI (CYP2EI) induction by alcohol, ketones, and fatty acids. Their excess causes alcoholic and nonalcoholic steatohepatitis. CYP2EI is also induced in Kupffer cells, promoting their activation and release of Inflammatory cytokines, including tumor necrosis factor (TNF)-α The TNF-α inhibitor pentoxifylline decreased mortality from alcoholic hepatitis. Polyenylphosphatidylcholine (PPC), an antioxidant phosphatidylcholine mixture extracted from soybeans, 50% of which consists of the highly bioavailable dilinoleoylphosphatidylcholine, restores phospholipids of the damaged membranes and reactivates their enzymes, including phosphatidylethanolamine methyltransferase, needed for phospholipid regeneration. In baboons, PPC prevented cirrhosis by stimulating collagenase and by opposing lipid peroxidation, which produces the fibrogenic hydroxynonenal. PPC was beneficial in patients with alcoholic hepatitis, and it opposed fibrosis in heavy drinkers and decreased aminotransferases in patients with hepatitis C. The antioxidant silymarin also successfully opposed alcoholic cirrhosis in baboons, and in some but not all clinical trials; this effect also pertains to α -tocopherol. The anti-inflammatory corticosteroids and colchicine yielded mixed results. Finally, replacing long-chain with medium-chain triglycerides opposed the fatty liver experimentally and clinically. Copyright © 2004 by Current Science Inc.
引用
收藏
页码:60 / 65
页数:5
相关论文
共 55 条
[1]  
Raynard B., Balian A., Fallik D., Et al., Risk factors of fibrosis in alcohol-induced liver disease, Hepatology, 35, pp. 635-638, (2002)
[2]  
Anton R.F., Lieber C.S., Tabakoff B., Carbohydrate-deficient transferrin and gamma-glutamyltransferase for the detection and monitoring of alcohol use: Results from a multisite study, Alcohol Clin. Exp. Res., 26, pp. 1215-1222, (2002)
[3]  
Volpicelli J.R., Alterman A.I., Hayashida M., O'Brien C.P., Naltrexone in the treatment of alcohol dependence, Arch. Gen. Psychiatry, 49, pp. 876-880, (1992)
[4]  
Lieber C.S., Alcoholic liver disease: New insights in pathogenesis lead to new treatments, J. Hepatology, 32, pp. 113-128, (2000)
[5]  
Duce A.M., Ortiz P., Cabrero C., Mato J.M., S-adenosyl-L-methionine synthetase and phospholipid methyltransferase are inhibited in human cirrhosis, Hepatology, 8, pp. 65-68, (1988)
[6]  
Lieber C.S., Alcoholic liver injury: Pathogenesis and therapy in 2001, Pathol. Biol., 49, pp. 738-752, (2001)
[7]  
Lieber C.S., Casini A., DeCarli L.M., Et al., S-adenosyl-L-methionine attenuates alcohol-induced liver injury in the baboon, Hepatology, 11, pp. 165-172, (1990)
[8]  
Frezza M., Surrenti C., Manzillo G., Et al., Oral S-adenosylmethionine in the symptomatic treatment of intrahepatic cholestasis: A double-blind placebo controlled study, Gastroenterology, 99, pp. 211-215, (1990)
[9]  
Vendemiale G., Altomare E., Trizio T., Et al., Effect of oral S-adenosyl-L-methionine on hepatic glutathione in patients with liver disease, Scand. J. Gastroenterol., 24, pp. 407-415, (1989)
[10]  
Mato J.M., Camara J., Fernandez de Paz J., Et al., S-Adenosylmethionine in alcoholic liver cirrhosis: A randomized, placebo-controlled, double-blind, multicentre clinical trial, J. Hepatology, 30, pp. 1081-1089, (1999)